KASID
Search
- Page Path
- HOME > Search
Reviews
- IBD
- The practice of fecal microbiota transplantation in inflammatory bowel disease
- Umang Arora, Saurabh Kedia, Vineet Ahuja
- Intest Res 2024;22(1):44-64. Published online November 21, 2023
- DOI: https://doi.org/10.5217/ir.2023.00085
-
Abstract
PDF
PubReader
ePub - Current evidence posits a central role for gut microbiota and the metabolome in the pathogenesis and progression of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) has been established as a means to manipulate this microbiome safely and sustainably. Several aspects of the technical improvement including pretreatment with antibiotics, use of frozen stool samples as well as short donor-to-recipient time are proposed to improve its response rates. Its efficacy in ulcerative colitis has been proven in clinical trials while data is emerging for Crohn’s disease. This review describes briefly the biology behind FMT, the available evidence for its use in IBD, and the host, recipient and procedural factors which determine the clinical outcomes.
-
Citations
Citations to this article as recorded by
- Advances in Fecal Microbiota Transplantation for Gut Dysbiosis‐Related Diseases
Shuna Hou, Jiachen Yu, Yongshuang Li, Duoyi Zhao, Zhiyu Zhang
Advanced Science.2025;[Epub] CrossRef - Gut Microbial Targets in Inflammatory Bowel Disease: Current Position and Future Developments
Naveen Sivakumar, Ashwin Krishnamoorthy, Harshita Ryali, Ramesh P. Arasaradnam
Biomedicines.2025; 13(3): 716. CrossRef - Medical management of acute severe ulcerative colitis in the hospitalized patient
Loren G Rabinowitz, Ajay Gade, Joseph D. Feuerstein
Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef - Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study
Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon
The Korean Journal of Internal Medicine.2024; 39(5): 783. CrossRef - Microbiome-based therapeutics for Parkinson's disease
Adam M. Hamilton, Ian N. Krout, Alexandria C. White, Timothy R. Sampson
Neurotherapeutics.2024; 21(6): e00462. CrossRef
- Advances in Fecal Microbiota Transplantation for Gut Dysbiosis‐Related Diseases
- 5,741 View
- 342 Download
- 5 Crossref
- IBD
- Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease
- Himani Pandey, Dheeraj Jain, Daryl W. T. Tang, Sunny H. Wong, Devi Lal
- Intest Res 2024;22(1):15-43. Published online November 8, 2023
- DOI: https://doi.org/10.5217/ir.2023.00080
-
Abstract
PDFPubReaderePub
- Inflammatory bowel disease (IBD) is a multifactorial disease, which is thought to be an interplay between genetic, environment, microbiota, and immune-mediated factors. Dysbiosis in the gut microbial composition, caused by antibiotics and diet, is closely related to the initiation and progression of IBD. Differences in gut microbiota composition between IBD patients and healthy individuals have been found, with reduced biodiversity of commensal microbes and colonization of opportunistic microbes in IBD patients. Gut microbiota can, therefore, potentially be used for diagnosing and prognosticating IBD, and predicting its treatment response. Currently, there are no curative therapies for IBD. Microbiota-based interventions, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, have been recognized as promising therapeutic strategies. Clinical studies and studies done in animal models have provided sufficient evidence that microbiota-based interventions may improve inflammation, the remission rate, and microscopic aspects of IBD. Further studies are required to better understand the mechanisms of action of such interventions. This will help in enhancing their effectiveness and developing personalized therapies. The present review summarizes the relationship between gut microbiota and IBD immunopathogenesis. It also discusses the use of gut microbiota as a noninvasive biomarker and potential therapeutic option.
-
Citations
Citations to this article as recorded by- Chitosan and its derivatives: A novel approach to gut microbiota modulation and immune system enhancement
Great Iruoghene Edo, Alice Njolke Mafe, Ali B.M. Ali, Patrick Othuke Akpoghelie, Emad Yousif, Jesse Innocent Apameio, Endurance Fegor Isoje, Ufuoma Augustina Igbuku, Yasal Garba, Arthur Efeoghene Athan Essaghah, Dina S. Ahmed, Huzaifa Umar, Dilber Uzun Oz
International Journal of Biological Macromolecules.2025; 289: 138633. CrossRef - Advances in bio-polymer coatings for probiotic microencapsulation: chitosan and beyond for enhanced stability and controlled release
Great Iruoghene Edo, Alice Njolke Mafe, Nawar. F. Razooqi, Ebuka Chukwuma Umelo, Tayser Sumer Gaaz, Endurance Fegor Isoje, Ufuoma Augustina Igbuku, Patrick Othuke Akpoghelie, Rapheal Ajiri Opiti, Arthur Efeoghene Athan Essaghah, Dina S. Ahmed, Huzaifa Uma
Designed Monomers and Polymers.2025; 28(1): 1. CrossRef - Helminths in alternative therapeutics of inflammatory bowel disease
Himani Pandey, Daryl W. T. Tang, Sunny H. Wong, Devi Lal
Intestinal Research.2025; 23(1): 8. CrossRef - Protective effect of low-dose lactulose in dextran sulfate sodium induced ulcerative colitis model of rats
Min Cui, Wei-Ming Yang, Ping Yao
Scientific Reports.2025;[Epub] CrossRef - Unraveling the Role of Fusobacterium nucleatum in Colorectal Cancer: Molecular Mechanisms and Pathogenic Insights
Linda Galasso, Fabrizio Termite, Irene Mignini, Giorgio Esposto, Raffaele Borriello, Federica Vitale, Alberto Nicoletti, Mattia Paratore, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
Cancers.2025; 17(3): 368. CrossRef - Lactobacillus vaginalis alleviates DSS induced colitis by regulating the gut microbiota and increasing the production of 3-indoleacrylic acid
Zhuoya Wang, Tian Liu, Li Liu, Jian Xie, Furui Tang, Yimin Pi, Yuchun Zhong, Zhidong He, Wenming Zhang, Cihua Zheng
Pharmacological Research.2025; 213: 107663. CrossRef - Therapeutic systems based on natural gut microbiota modulators: the latest advances in the treatment of inflammatory bowel disease
Zelin Guan, Peilin Niu, Qichao Tan, Yidong Wang, Shujing Deng, Danyang Wang, Kai Dong, Jianfeng Xing, Cuiyu You
Materials Advances.2025; 6(5): 1578. CrossRef - Metabolic musculoskeletal disorders in patients with inflammatory bowel disease
Young Joo Yang, Seong Ran Jeon
The Korean Journal of Internal Medicine.2025; 40(2): 181. CrossRef - Photobiomodulation and the oral-gut microbiome axis: therapeutic potential and challenges
Neda Hakimiha, Somayeh Jahani Sherafat, E-Liisa Laakso, Reza Fekrazad
Frontiers in Medicine.2025;[Epub] CrossRef - Editorial: Environments-pathogens-the gut microbiota and host diseases
Jinbo Xiong, Zunji Shi
Frontiers in Microbiology.2024;[Epub] CrossRef - Endoplasmic reticulum stress: A possible connection between intestinal inflammation and neurodegenerative disorders
Giorgio Vivacqua, Romina Mancinelli, Stefano Leone, Rosa Vaccaro, Ludovica Garro, Simone Carotti, Ludovica Ceci, Paolo Onori, Luigi Pannarale, Antonio Franchitto, Eugenio Gaudio, Arianna Casini
Neurogastroenterology & Motility.2024;[Epub] CrossRef - Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies
Neelakanta Sarvashiva Kiran, Chandrashekar Yashaswini, Rahul Maheshwari, Sankha Bhattacharya, Bhupendra G. Prajapati
ACS Pharmacology & Translational Science.2024; 7(4): 967. CrossRef - Healing from Within: How Gut Microbiota Predicts IBD Treatment Success—A Systematic Review
Luana Alexandrescu, Alina Doina Nicoara, Doina Ecaterina Tofolean, Alexandra Herlo, Andreea Nelson Twakor, Cristina Tocia, Anamaria Trandafir, Andrei Dumitru, Eugen Dumitru, Cristian Florentin Aftenie, Ionela Preotesoiu, Elena Dina, Ioan Tiberiu Tofolean
International Journal of Molecular Sciences.2024; 25(15): 8451. CrossRef - Effect of Mutant and Engineered High-Acetate-Producing Saccharomyces cerevisiae var. boulardii Strains in Dextran Sodium Sulphate-Induced Colitis
Sara Deleu, Inge Jacobs, Jorge F. Vazquez Castellanos, Sare Verstockt, Bruna Trindade de Carvalho, Ana Subotić, Bram Verstockt, Kaline Arnauts, Lowie Deprez, Eva Vissers, Matthias Lenfant, Greet Vandermeulen, Gert De Hertogh, Kristin Verbeke, Gianluca Mat
Nutrients.2024; 16(16): 2668. CrossRef - The emerging role of the gut microbiota and its application in inflammatory bowel disease
Xiu Wang, Jianhua Peng, Peipei Cai, Yuxuan Xia, Chengxue Yi, Anquan Shang, Francis Atim Akanyibah, Fei Mao
Biomedicine & Pharmacotherapy.2024; 179: 117302. CrossRef - Bifidogenic Effect of Human Milk Oligosaccharides on Pediatric IBD Fecal Microbiota
Nize Otaru, Danica Bajic, Pieter Van den Abbeele, Saskia Vande Velde, Stephanie Van Biervliet, Robert E. Steinert, Ateequr Rehman
Microorganisms.2024; 12(10): 1977. CrossRef - Analysis of the Preventive Effect of Lonicera caerulea Pomace and Its Isolated Components on Colitis in Mice Based on Gut Microbiota and Serum Metabolomics
Zinuo Zhou, Xinwen Huang, Baixi Zhang
Antioxidants.2024; 13(12): 1478. CrossRef - Gut microbiota mediated T cells regulation and autoimmune diseases
Nabeel Khalid Bhutta, Xiujin Xu, Cuiqin Jian, Yifan Wang, Yi Liu, Jinlyu Sun, Bingnan Han, Shandong Wu, Ansar Javeed
Frontiers in Microbiology.2024;[Epub] CrossRef - Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects
Yibing Hu, Zhenping Wu, Xiaoyun Yang, Jin Ding, Qunying Wang, Hao Fang, Lujian Zhu, Minli Hu
BMC Microbiology.2024;[Epub] CrossRef
- Chitosan and its derivatives: A novel approach to gut microbiota modulation and immune system enhancement
- 10,424 View
- 470 Download
- 20 Web of Science
- 19 Crossref
Case Report
- Inflammatory bowel diseases
- Incidental benefits after fecal microbiota transplant for ulcerative colitis
- Ramit Mahajan, Vandana Midha, Arshdeep Singh, Varun Mehta, Yogesh Gupta, Kirandeep Kaur, Ritu Sudhakar, Anmol Singh Pannu, Dharmatma Singh, Ajit Sood
- Intest Res 2020;18(3):337-340. Published online April 22, 2020
- DOI: https://doi.org/10.5217/ir.2019.00108
-
Abstract
PDFPubReaderePub
- Gut dysbiosis can result in several diseases, including infections (Clostridium difficile infection and infectious gastroenteritis), autoimmune diseases (inflammatory bowel disease, diabetes, and allergic disorders), behavioral disorders and other conditions like metabolic syndrome and functional gastrointestinal disorders. Amongst various therapies targeting gut microbiome, fecal microbiota transplantation (FMT) is becoming a focus in the public media and peer reviewed literature. We have been using FMT for induction of remission in patients with moderate to severe active ulcerative colitis (UC) and also for subsequent maintenance of remission. Four cases reported incidental benefits while being treated with FMT for UC. These included weight loss (n=1), improvement in hair loss (n=1), amelioration of axial arthritis (n=1) and improvement in allergic rhinitis (n=1), thereby suggesting potential clinical applications of FMT in treating extraintestinal diseases associated with gut dysbiosis.
-
Citations
Citations to this article as recorded by- Fecal microbiota transplantation in allergic diseases
Ece Tüsüz Önata, Öner Özdemir
World Journal of Methodology.2025;[Epub] CrossRef - 16S rRNA sequencing-based evaluation of the protective effects of key gut microbiota on inhaled allergen-induced allergic rhinitis
Yi Tang, Yongchuan She, Danping Chen, Yibo Zhou, Dan Xie, Zhai Liu
Frontiers in Microbiology.2025;[Epub] CrossRef - α‐Lipoic acid alleviates dextran sulfate sodium salt‐induced ulcerative colitis via modulating the Keap1–Nrf2 signaling pathway and inhibiting ferroptosis
Peng Jiang, Zongzhen Zhai, Linxian Zhao, Kai Zhang, Liwei Duan
Journal of the Science of Food and Agriculture.2024; 104(3): 1679. CrossRef - Effects of dietary imbalances of micro- and macronutrients on the ocular microbiome and its implications in dry eye disease
Madeline Pilkington, Declan Lloyd, Brad Guo, Stephanie L. Watson, Kenneth Gek-Jin Ooi
Exploration of Medicine.2024; : 127. CrossRef - Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease
Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi
Intestinal Research.2023; 21(1): 148. CrossRef - Case report: Fecal microbiota transplantation in refractory ankylosing spondylitis
Lei Wang, Zhimin Wei, Fei Pan, Chuan Song, Lihua Peng, Yunsheng Yang, Feng Huang
Frontiers in Immunology.2023;[Epub] CrossRef - Gut-spine axis: a possible correlation between gut microbiota and spinal degenerative diseases
Tadatsugu Morimoto, Takaomi Kobayashi, Toshihiko Kakiuchi, Motohiro Esaki, Masatsugu Tsukamoto, Tomohito Yoshihara, Hirohito Hirata, Shoji Yabuki, Masaaki Mawatari
Frontiers in Microbiology.2023;[Epub] CrossRef - Gut microbiota changes in patients with spondyloarthritis: A systematic review
Lei Wang, Yiwen Wang, Pei Zhang, Chuan Song, Fei Pan, Gang Li, Lihua Peng, Yunsheng Yang, Zhimin Wei, Feng Huang
Seminars in Arthritis and Rheumatism.2022; 52: 151925. CrossRef - Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases
Yun Wang, Sheng Zhang, Thomas J. Borody, Faming Zhang
Chinese Medical Journal.2022;[Epub] CrossRef - Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review
Xinpei Gu, Qin Lu, Chengcheng Zhang, Zhewei Tang, Liuxi Chu
Seminars in Liver Disease.2021; 41(04): 495. CrossRef - Intestinal microbiota and inflammatory bowel diseases
Chang Soo Eun
Journal of the Korean Medical Association.2021; 64(9): 588. CrossRef
- Fecal microbiota transplantation in allergic diseases
- 7,910 View
- 175 Download
- 10 Web of Science
- 11 Crossref
Review
- IBD
- Current new challenges in the management of ulcerative colitis
- Tomohiro Fukuda, Makoto Naganuma, Takanori Kanai
- Intest Res 2019;17(1):36-44. Published online January 25, 2019
- DOI: https://doi.org/10.5217/ir.2018.00126
-
Abstract
PDFPubReaderePub
- Ulcerative colitis (UC) is a chronic inflammatory condition of the gastrointestinal tract. Although the cause of UC is postulated to be multifactorial in nature, including genetic predisposition, epithelial barrier defects, dysregulation of immune responses, and environmental factors, the specific pathogenesis of UC is still incompletely understood. In the treatment of UC so far, a method of suppressing immunity and treating it has been mainstream. Immunosuppressant drugs, including thiopurines (azathioprine or 6-mercaptopurine), anti-tumor necrosis factor-α (anti-TNF-α) antibody (infliximab and adalimumab), and calcineurin inhibitor, can be used in treat patients with corticosteroid-dependent and/or corticosteroid-refractory moderateto- severe UC. Recently, in addition to such a conventional therapeutic agent, golimumab, which is the first transgenic human monoclonal anti-TNF-α antibody to be fabricated, anti α-4/β-7 integrin antibody, and Janus kinase inhibitor have been reported to novel immunosuppressant therapy. Furthermore, other treatments with unique mechanisms different from immunosuppression, have also been suggested, including fecal microbiota transplantation and Indigo naturalis, which is a Chinese herbal medicine. We compared the features and efficacy of these new treatments. In this issue, the features and treatment options for these new treatments is reviewed.
-
Citations
Citations to this article as recorded by- Systemic investigation of the mechanism underlying the therapeutic effect of Astragalus membranaceus in ulcerative colitis
Jingxin Mao, Lihong Tan, Cheng Tian, Wenxiang Wang, YanLin Zou, Zhaojing Zhu, Yan Li
The American Journal of the Medical Sciences.2025; 369(2): 238. CrossRef - Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity
Seung Yong Shin, Hee Sung Kim, Kisung Kim, Chang Won Choi, Jung Min Moon, Jeong Wook Kim, Hyun Jin Joo, Jeongkuk Seo, Muhyeon Sung, Chang Hwan Choi
The Korean Journal of Internal Medicine.2024; 39(1): 68. CrossRef - Recent Updates on the Therapeutics Benefits, Clinical Trials, and Novel
Delivery Systems of Chlorogenic Acid for the Management of Diseases with a
Special Emphasis on Ulcerative Colitis
Ranjit K. Harwansh, Hemant Bhati, Rohitas Deshmukh
Current Pharmaceutical Design.2024; 30(6): 420. CrossRef - Dose-dependent effects of cobalt chloride supplementation in a rat model of acetic acid-induced ulcerative colitis
Akinleye Stephen Akinrinde, Ekundayo Stephen Samuel, Bisi Olajumoke Adeoye
Comparative Clinical Pathology.2024; 33(5): 705. CrossRef - Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD)
Daniela Kosorínová, Pavlína Suchá, Zuzana Havlíčeková, Marek Pršo, Pavol Dvoran, Peter Bánovčin
Česko-slovenská pediatrie.2024; 79(4): 213. CrossRef - Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study
Brian G. Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Silvio Danese, Edward V. Loftus, Ian Beales, Stefan Schreiber, Hyo Jong Kim, Margaux Faes, Angela de Haas, Tomasz Masior, Christine Rudolph, Laurent Peyrin‐Biroulet
Alimentary Pharmacology & Therapeutics.2024; 60(5): 563. CrossRef - Loganin Ameliorates Acute Kidney Injury and Restores Tofacitinib Metabolism in Rats: Implications for Renal Protection and Drug Interaction
Hyeon Gyeom Choi, So Yeon Park, Sung Hun Bae, Sun-Young Chang, So Hee Kim
Biomolecules & Therapeutics.2024; 32(5): 601. CrossRef - Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi
Gut Pathogens.2024;[Epub] CrossRef - Protective effect of (E)-(2,4-dihydroxy)-α-aminocinnamic acid, a hydroxy cinnamic acid derivative, in an ulcerative colitis model induced by TNBS
Astrid Mayleth Rivera Antonio, Itzia Irene Padilla Martínez, Yazmín Karina Márquez-Flores, Alan Hipólito Juárez Solano, Mónica A. Torres Ramos, Martha Cecilia Rosales Hernández
Bioscience Reports.2024;[Epub] CrossRef - Lactiplantibacillus plantarum BW2013 protects mucosal integrity and modulates gut microbiota of mice with colitis
Xiaohui Niu, Qian Li, Na Luan, Jia Liu, Michael Zhang, Jun An, Zuming Li, Zhihui Bai, Ran Xia, Zhichao Wu
Canadian Journal of Microbiology.2023; 69(4): 158. CrossRef - Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
Intestinal Research.2023; 21(2): 174. CrossRef - Effect and mechanism of total ginsenosides repairing SDS‑induced Drosophila enteritis model based on MAPK pathway
Hang Su, Yujing Tan, Zhijiang Zhou, Chunjuan Wang, Wei Chen, Jinlong Wang, Haiming Sun
Experimental and Therapeutic Medicine.2023;[Epub] CrossRef - Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats
Jong Mun Won, Hyeon Gyeom Choi, So Yeon Park, Jang-Hee Kim, So Hee Kim
Pharmaceutics.2023; 15(9): 2195. CrossRef - Knowledge, attitude, and practice of patients living with inflammatory bowel disease: A cross-sectional study
Xiao-Xiao Shao, Lu-Yan Fang, Xu-Ri Guo, Wei-Zhong Wang, Rui-Xin Shi, Dao-Po Lin
World Journal of Gastroenterology.2023; 29(43): 5818. CrossRef - Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
Danny Con, Bridgette Andrew, Steven Nicolaides, Daniel R van Langenberg, Abhinav Vasudevan
Intestinal Research.2022; 20(1): 101. CrossRef - Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
Su Bum Park, Seong-Jung Kim, Jun Lee, Yoo Jin Lee, Dong Hoon Baek, Geom Seog Seo, Eun Soo Kim, Sang-Wook Kim, So Yeong Kim
BMC Gastroenterology.2022;[Epub] CrossRef - Protective effects of Ligularia fischeri root extracts against ulcerative colitis in mice through activation of Bcl-2/Bax signalings
Yong-Ping Fu, Huan Yuan, Yan Xu, Ru-Ming Liu, Yi Luo, Jian-Hui Xiao
Phytomedicine.2022; 99: 154006. CrossRef - Traditional Chinese Medicine Alleviates Ulcerative Colitis via Modulating Gut Microbiota
Wan Feng, Lei Zhu, Hong Shen, Jin-Yi Wan
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef - Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
Soo Min Ahn, Jonggi Choi, Byong Duk Ye, Suk-Kyun Yang, Ji Seon Oh, Yong‑Gil Kim, Chang-Keun Lee, Bin Yoo, Sang Hyoung Park, Seokchan Hong
Gut and Liver.2022; 16(4): 567. CrossRef - Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef - “Two-birds-one-stone” colon-targeted nanomedicine treats ulcerative colitis via remodeling immune microenvironment and anti-fibrosis
Jiaxin Zhang, Ante Ou, Xueping Tang, Rong Wang, Yujuan Fan, Yuefei Fang, Yuge Zhao, Pengfei Zhao, Dongying Chen, Bing Wang, Yongzhuo Huang
Journal of Nanobiotechnology.2022;[Epub] CrossRef - Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
Soo-Kyung Park, Sang-Bum Kang, SangSoo Kim, Tae Oh Kim, Jae Myung Cha, Jong Pil Im, Chang Hwan Choi, Eun Soo Kim, Geom Seog Seo, Chang Soo Eun, Dong Soo Han, Dong Il Park
The Korean Journal of Internal Medicine.2022; 37(5): 949. CrossRef - Effects of Dextran Sulfate Sodium-Induced Ulcerative Colitis on the Disposition of Tofacitinib in Rats
Sung Hun Bae, Hyo Sung Kim, Hyeon Gyeom Choi, Sun-Young Chang, So Hee Kim
Biomolecules & Therapeutics.2022; 30(6): 510. CrossRef - Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with N-Dimethylnitrosamine-Induced Liver Cirrhosis
Sung Hun Bae, Hyeon Gyeom Choi, So Yeon Park, Sun-Young Chang, Hyoungsu Kim, So Hee Kim
Pharmaceutics.2022; 14(12): 2684. CrossRef - Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016
Katsuyoshi Matsuoka, Ataru Igarashi, Noriko Sato, Yuri Isono, Maki Gouda, Katsuhiko Iwasaki, Ayako Shoji, Tadakazu Hisamatsu
Journal of Crohn's and Colitis.2021; 15(3): 358. CrossRef - Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
Yong Il Lee, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Gut and Liver.2021; 15(2): 232. CrossRef - Efficacy and Safety of Fecal Microbiota Transplantation and Prospect of Microbe-based Therapies for Inflammatory Bowel Disease
Hoon Gil Jo, Geom Seog Seo
The Korean Journal of Gastroenterology.2021; 78(1): 31. CrossRef - The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity
Seong Kyun Kim, Ho-Su Lee, Beom-Jun Kim, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park, Masanao Nakamura
Canadian Journal of Gastroenterology and Hepatology.2021; 2021: 1. CrossRef - Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef - Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Joo Hye Song, Eun Ae Kang, Soo-Kyung Park, Sung Noh Hong, You Sun Kim, Ki Bae Bang, Kyeong Ok Kim, Hong Sub Lee, Sang-Bum Kang, Seung Yong Shin, Eun Mi Song, Jong Pil Im, Chang Hwan Choi
Gut and Liver.2021; 15(5): 752. CrossRef - Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef - Current status of inflammatory bowel diseases in Korea
Suk-Kyun Yang
Journal of the Korean Medical Association.2021; 64(9): 572. CrossRef - Intestinal microbiota and inflammatory bowel diseases
Chang Soo Eun
Journal of the Korean Medical Association.2021; 64(9): 588. CrossRef - Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
You Sun Kim
Intestinal Research.2021; 19(4): 357. CrossRef - Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study
Jin Wook Lee, Eun Mi Song, Sung-Ae Jung, Sung Hoon Jung, Kwang Woo Kim, Seong-Joon Koh, Hyun Jung Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Journal of Korean Medical Science.2021;[Epub] CrossRef - Development of a Machine Learning Model to Distinguish between Ulcerative Colitis and Crohn’s Disease Using RNA Sequencing Data
Soo-Kyung Park, Sangsoo Kim, Gi-Young Lee, Sung-Yoon Kim, Wan Kim, Chil-Woo Lee, Jong-Lyul Park, Chang-Hwan Choi, Sang-Bum Kang, Tae-Oh Kim, Ki-Bae Bang, Jaeyoung Chun, Jae-Myung Cha, Jong-Pil Im, Kwang-Sung Ahn, Seon-Young Kim, Dong-Il Park
Diagnostics.2021; 11(12): 2365. CrossRef - Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef - Intestinal Epithelial Deletion of Sphk1 Prevents Colitis-Associated Cancer Development by Inhibition of Epithelial STAT3 Activation
Seung Bin Park, Byung-il Choi, Beom Jae Lee, Nam Joo Kim, Yoon A. Jeong, Moon Kyung Joo, Hyo Jung Kim, Jong-Jae Park, Jae Seon Kim, Yoon-Seok Noh, Hyun Joo Lee
Digestive Diseases and Sciences.2020; 65(8): 2284. CrossRef - Simple determination and quantification of tofacitinib, a JAK inhibitor, in rat plasma, urine and tissue homogenates by HPLC and its application to a pharmacokinetic study
Ji Eun Kim, Mun Young Park, So Hee Kim
Journal of Pharmaceutical Investigation.2020; 50(6): 603. CrossRef - Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats
Eun Hye Gwak, Hee Young Yoo, So Hee Kim
Biomolecules & Therapeutics.2020; 28(4): 361. CrossRef - Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion
Sung Hun Bae, Sun-Young Chang, So Hee Kim
Pharmaceutics.2020; 12(8): 714. CrossRef - The amelioration of ulcerative colitis induced by Dinitrobenzenesulfonic acid with Radix Hedysari
Gengen Shi, Donghan Wang, Zhiyuan Xue, Xianglin Zhou, Yaoyao Fang, Shilan Feng, Lianggong Zhao
Journal of Food Biochemistry.2020;[Epub] CrossRef - Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism
Ji Sang Lee, So Hee Kim
Pharmaceutics.2019; 11(7): 318. CrossRef - Dermatologische Komplikationen unter Therapie mit Biologika bei entzündlichen Autoimmunerkrankungen
Wiebke Sondermann, Saskia Herz, Elsa Sody, Andreas Körber
JDDG: Journal der Deutschen Dermatologischen Gesellschaft.2019; 17(10): 1029. CrossRef - Dermatological complications of therapy with biologics in inflammatory autoimmune diseases
Wiebke Sondermann, Saskia Herz, Elsa Sody, Andreas Körber
JDDG: Journal der Deutschen Dermatologischen Gesellschaft.2019; 17(10): 1029. CrossRef
- Systemic investigation of the mechanism underlying the therapeutic effect of Astragalus membranaceus in ulcerative colitis
- 9,895 View
- 439 Download
- 46 Web of Science
- 45 Crossref
Original Article
- IBD
- Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis
- Ajit Sood, Ramit Mahajan, Garima Juyal, Vandana Midha, Charanpreet Singh Grewal, Varun Mehta, Arshdeep Singh, Mohan C Joshi, Vikram Narang, Kirandeep Kaur, Hasrat Sidhu
- Intest Res 2019;17(1):78-86. Published online November 20, 2018
- DOI: https://doi.org/10.5217/ir.2018.00089
-
Abstract
PDF
Supplementary MaterialPubReaderePub - Background/Aims
Four high-quality randomized controlled trials have proven the efficacy of fecal microbiota transplantation (FMT) in active ulcerative colitis (UC). We assessed the efficacy of FMT in a real-world setting involving steroid-dependent patients with UC.
Methods
This was a single-center prospective analysis of data from steroid-dependent patients with UC treated with FMT from September 2015 to September 2017 at the Dayanand Medical College, a tertiary care center in India. Fecal samples from random unrelated donors were administered through colonoscopy at weeks 0, 2, 6, 10, 14, 18, and 22. The primary outcome was achievement of steroid-free clinical remission, and the secondary outcomes were clinical response and endoscopic remission at 24 weeks. Modified intention-to-treat analysis was performed, which included subjects who underwent at least 1 FMT.
Results
Of 345 patients with UC treated during the study period, 49 (14.2%) had steroid-dependent UC. Of these 49 patients, 41 underwent FMT: 33 completed 7 sessions over 22 weeks according to the protocol, and 8 discontinued treatment (non-response, 5; lost to follow-up, 2; and fear of adverse effects, 1). At week 24, steroid-free clinical remission was achieved in 19 out of 41 (46.3%) patients, whereas clinical response and endoscopic remission were achieved in 31 out of 41 (75.6%) and 26 out of 41 (63.4%) patients, respectively. All patients with clinical response were able to withdraw steroids. There were no serious adverse events necessitating discontinuation.
Conclusions
A multisession FMT via the colonoscopic route is a promising therapeutic option for patients with steroid-dependent UC, as it can induce clinical remission and aid in steroid withdrawal. -
Citations
Citations to this article as recorded by- Inflammatory bowel disease in south Asia: a scoping review
Shabari Shenoy, Anuraag Jena, Carrie Levinson, Vishal Sharma, Parakkal Deepak, Tina Aswani-Omprakash, Shaji Sebastian, Jean-Frederic Colombel, Manasi Agrawal
The Lancet Gastroenterology & Hepatology.2025; 10(3): 259. CrossRef - Microbiota transplant therapy in inflammatory bowel disease: advances and mechanistic insights
Daphne Moutsoglou, Pavithra Ramakrishnan, Byron P. Vaughn
Gut Microbes.2025;[Epub] CrossRef - The practice of fecal microbiota transplantation in inflammatory bowel disease
Umang Arora, Saurabh Kedia, Vineet Ahuja
Intestinal Research.2024; 22(1): 44. CrossRef - Current perspectives on fecal microbiota transplantation in inflammatory bowel disease
Arshdeep Singh, Vandana Midha, Nar Singh Chauhan, Ajit Sood
Indian Journal of Gastroenterology.2024; 43(1): 129. CrossRef - Artemisia argyi polyphenols Attenuates DSS-induced colitis in mice by regulating the structural composition of gut microbiota
Huaqiang Zhang, Zhonghua Hao, Ruya Zhang, Jiang Tong, Xiaoke Wang, Jingjing Liu, Yingkui Gao, Xuefang Wang, Qing Su, Haojie Wen, Yi Fan, Fang Liu, Xiao Li, Chao Tong, Xuebing Wang
Phytomedicine.2024; 132: 155897. CrossRef - Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study
Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon
The Korean Journal of Internal Medicine.2024; 39(5): 783. CrossRef - Fecal transplantation for treatment of inflammatory bowel disease
Aamer Imdad, Natasha G Pandit, Muizz Zaman, Nathan Zev Minkoff, Emily E Tanner-Smith, Oscar G Gomez-Duarte, Sari Acra, Maribeth R Nicholson
Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef - Single-Donor and Pooling Strategies for Fecal Microbiota Transfer Product Preparation in Ulcerative Colitis: A Systematic Review and Meta-analysis
Benoît Levast, Mathieu Fontaine, Stéphane Nancey, Pierre Dechelotte, Joël Doré, Philippe Lehert
Clinical and Translational Gastroenterology.2023; 14(5): e00568. CrossRef - Lithium carbonate alleviates colon inflammation through modulating gut microbiota and Treg cells in a GPR43-dependent manner
Shengjie Huang, Shiping Hu, Shuang Liu, Bo Tang, Yaojiang Liu, Li Tang, Yuanyuan Lei, Li Zhong, Shiming Yang, Song He
Pharmacological Research.2022; 175: 105992. CrossRef - Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed
Tiziana LARUSSA, Ludovico ABENAVOLI, Giulia FABIANO, Maria A. MANCUSO, Natale POLIMENI, Dan L. DUMITRASCU, Francesco LUZZA
Minerva Gastroenterology.2022;[Epub] CrossRef - Fecal microbiota transplantation for induction of remission, maintenance and rescue in patients with corticosteroid-dependent ulcerative colitis: a long-term follow-up real-world cohort study
Avnish Kumar Seth, Priti Jain
Intestinal Research.2022; 20(2): 251. CrossRef - Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota transplantation in patients with ulcerative colitis
Nia Paddison Rees, Walaa Shaheen, Christopher Quince, Chris Tselepis, Richard D Horniblow, Naveen Sharma, Andrew D Beggs, Tariq H Iqbal, Mohammed Nabil Quraishi
eBioMedicine.2022; 81: 104088. CrossRef - An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis
Taobi Huang, Jinlan Xu, Maoying Wang, Ke Pu, Longquan Li, Huiyun Zhang, Yuan Liang, Weiming Sun, Yuping Wang
Medicine.2022; 101(30): e29790. CrossRef - Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
Soo-Kyung Park, Sang-Bum Kang, SangSoo Kim, Tae Oh Kim, Jae Myung Cha, Jong Pil Im, Chang Hwan Choi, Eun Soo Kim, Geom Seog Seo, Chang Soo Eun, Dong Soo Han, Dong Il Park
The Korean Journal of Internal Medicine.2022; 37(5): 949. CrossRef - Early fecal microbiome transfer after donor defecation determines response in patients with moderate to severe ulcerative colitis
Arshdeep Singh, Ramit Mahajan, Bhavjeet Kaur Kahlon, Ashvin Singh Dhaliwal, Vandana Midha, Varun Mehta, Namita Bansal, Dharmatma Singh, Ajit Sood
Indian Journal of Gastroenterology.2022; 41(4): 389. CrossRef - Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
Intestinal Research.2022; 20(4): 452. CrossRef - Inflammatory bowel disease in India: challenges and opportunities
Alice Snell, Jonathan Segal, Jimmy Limdi, Rupa Banerjee
Frontline Gastroenterology.2021; 12(5): 390. CrossRef - Clinical Predictors of Response to Faecal Microbiota Transplantation in Patients with Active Ulcerative Colitis
Ajit Sood, Arshdeep Singh, Ramit Mahajan, Vandana Midha, Kirandeep Kaur, Dharmatma Singh, Namita Bansal, Khushdeep Dharni
Journal of Crohn's and Colitis.2021; 15(2): 238. CrossRef - Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study
Haiming Fang, Lian Fu, Xuejun Li, Chunxia Lu, Yuan Su, Kangwei Xiong, Lijiu Zhang
Microbial Cell Factories.2021;[Epub] CrossRef - Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis
Valentin Mocanu, Sabitha Rajaruban, Jerry Dang, Janice Y. Kung, Edward C. Deehan, Karen L. Madsen
Journal of Clinical Medicine.2021; 10(5): 959. CrossRef - Efficacy and Safety of Fecal Microbiota Transplantation and Prospect of Microbe-based Therapies for Inflammatory Bowel Disease
Hoon Gil Jo, Geom Seog Seo
The Korean Journal of Gastroenterology.2021; 78(1): 31. CrossRef - Intestinal microbiota and inflammatory bowel diseases
Chang Soo Eun
Journal of the Korean Medical Association.2021; 64(9): 588. CrossRef - The Role of Glucocorticoids in Inflammatory Diseases
Sybille D. Reichardt, Agathe Amouret, Chiara Muzzi, Sabine Vettorazzi, Jan P. Tuckermann, Fred Lühder, Holger M. Reichardt
Cells.2021; 10(11): 2921. CrossRef - Acceptability, tolerability, and safety of fecal microbiota transplantation in patients with active ulcerative colitis (AT&S Study)
Ajit Sood, Arshdeep Singh, Ramit Mahajan, Vandana Midha, Varun Mehta, Yogesh Kumar Gupta, Vikram Narang, Kirandeep Kaur
Journal of Gastroenterology and Hepatology.2020; 35(3): 418. CrossRef - Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening
Ting Zhang, Gaochen Lu, Zhe Zhao, Yafei Liu, Quan Shen, Pan Li, Yaoyao Chen, Haoran Yin, Huiquan Wang, Cicilia Marcella, Bota Cui, Lei Cheng, Guozhong Ji, Faming Zhang
Protein & Cell.2020; 11(4): 251. CrossRef - Efficacy of intestinal microbiota transplantation in ulcerative colitis: a review of current literature and knowledge
Krista M. Newman, Byron P. Vaughn
Minerva Gastroenterologica e Dietologica.2020;[Epub] CrossRef - Advances in the understanding of the intestinal micro-environment and inflammatory bowel disease
Peng-Guang Yan, Jing-Nan Li
Chinese Medical Journal.2020; 133(7): 834. CrossRef - Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
Journal of Digestive Diseases.2020; 21(3): 147. CrossRef - Enhancing patient adherence to fecal microbiota transplantation maintains the long-term clinical effects in ulcerative colitis
Qianqian Li, Ting Zhang, Xiao Ding, Liyuan Xiang, Bota Cui, Heena Buch, Faming Zhang
European Journal of Gastroenterology & Hepatology.2020; 32(8): 955. CrossRef - Incidental benefits after fecal microbiota transplant for ulcerative colitis
Ramit Mahajan, Vandana Midha, Arshdeep Singh, Varun Mehta, Yogesh Gupta, Kirandeep Kaur, Ritu Sudhakar, Anmol Singh Pannu, Dharmatma Singh, Ajit Sood
Intestinal Research.2020; 18(3): 337. CrossRef - Fecal Microbiota Transplantation for Ulcerative Colitis: The Optimum Timing and Gut Microbiota as Predictors for Long-Term Clinical Outcomes
Qianqian Li, Xiao Ding, Kangjian Liu, Cicilia Marcella, Xiaolin Liu, Ting Zhang, Yafei Liu, Pan Li, Liyuan Xiang, Bota Cui, Jun Wang, Jianling Bai, Faming Zhang
Clinical and Translational Gastroenterology.2020; 11(8): e00224. CrossRef - Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis
Luciane de Fátima Caldeira, Helena H. Borba, Fernanda S. Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo, Udai P. Singh
PLOS ONE.2020; 15(9): e0238910. CrossRef - Efficacy and safety of fecal microbiota transplantation by washed preparation in patients with moderate to severely active ulcerative colitis
Min Chen, Xiao Lei Liu, Yu Jie Zhang, Yong Zhan Nie, Kai Chun Wu, Yong Quan Shi
Journal of Digestive Diseases.2020; 21(11): 621. CrossRef - Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy
Ajit Sood, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Dina Kao, David T Rubin, Charles N Bernstein
Crohn's & Colitis 360.2020;[Epub] CrossRef - Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta‐analysis
Hai Lan Zhao, Shu Zhen Chen, Hao Ming Xu, You Lian Zhou, Jie He, Hong Li Huang, Jing Xu, Yu Qiang Nie
Journal of Digestive Diseases.2020; 21(10): 534. CrossRef - Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia
Siew C Ng, Joyce Wing Yan Mak, Partha Pal, Rupa Banerjee
The Lancet Gastroenterology & Hepatology.2020; 5(12): 1089. CrossRef - Lithium Carbonate Treatment Alleviates Gut Inflammation Through Activating Treg Cell Responses in a Microbiota-Dependent Manner
Shengjie Huang, Bo Tang, Li Tang, Yaojiang Liu, Shuang Liu, Yuanyuan Lei, Shiping Hu, Li Zhong, Shiming Yang, Song He
SSRN Electronic Journal .2020;[Epub] CrossRef - Fecal Microbiota Transplantation in Intestinal Disorders: A Primer for Physicians
Ajit Sood, Vandana Midha, Harmeet Kaur, Arshdeep Singh
Journal of Gastrointestinal Infections.2020; 10(1): 16. CrossRef - Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of
steroid-dependent ulcerative colitis
Young-Seok Cho
Intestinal Research.2019; 17(1): 6. CrossRef - Intestinal microbiome as a novel therapeutic target for local and systemic inflammation
Kazuhiko Uchiyama, Yuji Naito, Tomohisa Takagi
Pharmacology & Therapeutics.2019; 199: 164. CrossRef - Role of Faecal Microbiota Transplantation for Maintenance of Remission in Patients With Ulcerative Colitis: A Pilot Study
Ajit Sood, Ramit Mahajan, Arshdeep Singh, Vandana Midha, Varun Mehta, Vikram Narang, Tarundeep Singh, Anmol Singh Pannu
Journal of Crohn's and Colitis.2019; 13(10): 1311. CrossRef - Evolution of fecal microbiota transplantation in methodology and ethical issues
Faming Zhang, Ting Zhang, Heming Zhu, Thomas J Borody
Current Opinion in Pharmacology.2019; 49: 11. CrossRef
- Inflammatory bowel disease in south Asia: a scoping review
- 10,674 View
- 281 Download
- 43 Web of Science
- 42 Crossref
Review
- IBD
- Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?
- Natalie Grace Fairhurst, Simon P. L. Travis
- Intest Res 2018;16(2):209-215. Published online April 30, 2018
- DOI: https://doi.org/10.5217/ir.2018.16.2.209
-
Abstract
PDFPubReaderePub
Faecal microbiota transplantation (FMT) has recently re-emerged as a viable therapeutic option for colonic disorders. Its efficacy has been proved in the treatment of
Clostridium difficile infection which has encouraged research into the use of FMT for other disorders involving gut dysbiosis, such as ulcerative colitis (UC), a chronic inflammatory disease characterized by relapsing and remitting colonic inflammation. Although the FMT protocol forC. difficile treatment is well established, there are numerous additional factors to consider when applying FMT to treat inflammatory diseases. Various studies have attempted to address these factors but technical inconsistency between reports has resulted in a failure to achieve clinically significant findings. Case reports of FMT in UC have shown favorable outcomes yet demonstrating these effects on a larger scale has proved difficult. The following review aims to explore these issues and to analyze why they may be hindering the progression of FMT therapy in UC.-
Citations
Citations to this article as recorded by- The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis
Adam Saleh, Shyon Parsa, Manuel Garza, Eamonn M.M. Quigley, Bincy P. Abraham
Digestive Diseases.2023; 41(4): 656. CrossRef - Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches
Jana Štofilová, Monika Kvaková, Anna Kamlárová, Emília Hijová, Izabela Bertková, Zuzana Guľašová
Biomedicines.2022; 10(9): 2236. CrossRef - Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience
M.C. Flux, Christopher A. Lowry
Neurobiology of Disease.2020; 135: 104578. CrossRef - In Situ Profiling of the Three Dominant Phyla Within the Human Gut Using TaqMan PCR for Pre-Hospital Diagnosis of Gut Dysbiosis
Young Jae Jo, Setu Bazie Tagele, Huy Quang Pham, YeonGyun Jung, Jerald Conrad Ibal, SeungDae Choi, Gi-Ung Kang, Sowon Park, Yunkoo Kang, Seung Kim, Hong Koh, Jae-Ho Shin
International Journal of Molecular Sciences.2020; 21(6): 1916. CrossRef - Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
Journal of Digestive Diseases.2020; 21(3): 147. CrossRef - Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability
Stephanie A. Flowers, Shubha Bhat, James C. Lee
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2020; 40(7): 704. CrossRef - Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis
Ajit Sood, Ramit Mahajan, Garima Juyal, Vandana Midha, Charanpreet Singh Grewal, Varun Mehta, Arshdeep Singh, Mohan C Joshi, Vikram Narang, Kirandeep Kaur, Hasrat Sidhu
Intestinal Research.2019; 17(1): 78. CrossRef - Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of
steroid-dependent ulcerative colitis
Young-Seok Cho
Intestinal Research.2019; 17(1): 6. CrossRef - Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis
Xiao Ding, Qianqian Li, Pan Li, Ting Zhang, Bota Cui, Guozhong Ji, Xiang Lu, Faming Zhang
Drug Safety.2019; 42(7): 869. CrossRef
- The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis
- 7,472 View
- 79 Download
- 11 Web of Science
- 9 Crossref
Case Reports
- IBD
-
Fecal microbiota transplantation for recurrent
Clostridium difficile infection in a patient with ulcerative colitis - Kosaku Nanki, Shinta Mizuno, Katsuyoshi Matsuoka, Keiko Ono, Shinya Sugimoto, Hiroki Kiyohara, Mari Arai, Moeko Nakashima, Kozue Takeshita, Keiichiro Saigusa, Mitsutoshi Senoh, Tadashi Fukuda, Makoto Naganuma, Haru Kato, Wataru Suda, Masahira Hattori, Takanori Kanai
- Intest Res 2018;16(1):142-146. Published online January 18, 2018
- DOI: https://doi.org/10.5217/ir.2018.16.1.142
-
Abstract
PDFPubReaderePub
Fecal microbiota transplantation (FMT) has been reported as a safe and effective therapy in patients with refractory and recurrent
Clostridium difficile infection (CDI). FMT has also been reported as a promising therapy in patients with ulcerative colitis (UC). Both, CDI and UC, are believed to be caused by dysbiosis, such as altered compositions or decreased diversity of the intestinal microbiota. This report describes a patient with UC in remission with a second recurrent episode of CDI, who was treated with FMT. A single FMT performed via colonoscopy completely resolved the patient's diarrhea and eradicatedC. difficile bacteriologically without any severe complications. Molecular biological analysis of the patient's fecal microbiota showed that FMT could dramatically change the altered composition of intestinal microbiota and restore its diversity. Despite the restoration of the intestinal microbiota, FMT could not prevent a relapse of UC in this patient. However, it improved the intestinal symptoms of CDI and could prevent further recurrences of CDI.-
Citations
Citations to this article as recorded by- Impact of Clostridioides difficile Infection on Clinical Outcomes in Hospitalized IBD Patients and the Role of Fecal Microbiota Transplantation: A Retrospective Cohort Study
Puo‐Hsien Le, Chyi‐Liang Chen, Chia‐Jung Kuo, Pai‐Jui Yeh, Chien‐Chang Chen, Yi‐Ching Chen, Cheng‐Tang Chiu, Hao‐Tsai Cheng, Yung‐Kuan Tsou, Yu‐Bin Pan, Cheng‐Hsun Chiu
The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef - Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or Recurrent Clostridioides difficile Infection among Patients with and without Inflammatory Bowel Disease: A Retrospective Cohort Study
Jing-Han Chen, Cheng-Hsun Chiu, Chien-Chang Chen, Yi-Ching Chen, Pai-Jui Yeh, Chia-Jung Kuo, Cheng-Tang Chiu, Hao-Tsai Cheng, Yu-Bin Pan, Puo-Hsien Le
Biomedicines.2024; 12(7): 1396. CrossRef - Case report: Fecal microbiota transplant for Clostridium difficile infection in a pregnant patient with acute severe ulcerative colitis
Hanyu Wang, Feihong Deng, Min Luo, Xuehong Wang
Frontiers in Immunology.2024;[Epub] CrossRef - The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease
Loris Riccardo Lopetuso, Sara Deleu, Lihi Godny, Valentina Petito, Pierluigi Puca, Federica Facciotti, Harry Sokol, Gianluca Ianiro, Luca Masucci, Maria Abreu, Iris Dotan, Samuel Paul Costello, Ailsa Hart, Tariq H Iqbal, Sudarshan Paramsothy, Maurizio San
Gut.2023; 72(9): 1642. CrossRef - Fecal microbiota transplantation as therapy for recurrent Clostridioides difficile infection is associated with amelioration of delirium and accompanied by changes in fecal microbiota and the metabolome
Kazuyoshi Gotoh, Yoshihiko Sakaguchi, Haru Kato, Hayato Osaki, Yasutaka Jodai, Mitsutaka Wakuda, Akira Také, Shunji Hayashi, Eri Morita, Takehiko Sugie, Yoichiro Ito, Naoki Ohmiya
Anaerobe.2022; 73: 102502. CrossRef - Management of Clostridioides difficile infection in patients with inflammatory bowel disease
Sahil Khanna
Intestinal Research.2021; 19(3): 265. CrossRef - Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
Journal of Digestive Diseases.2020; 21(3): 147. CrossRef - RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
Jung Hoon Song, You Sun Kim
Gut and Liver.2019; 13(1): 16. CrossRef - Current Status of Clostridium Difficile Infection
Akira Andoh, Shigeki Bamba
Nippon Daicho Komonbyo Gakkai Zasshi.2018; 71(10): 456. CrossRef
- Impact of Clostridioides difficile Infection on Clinical Outcomes in Hospitalized IBD Patients and the Role of Fecal Microbiota Transplantation: A Retrospective Cohort Study
- 8,965 View
- 87 Download
- 8 Web of Science
- 9 Crossref
- Fecal microbiota transplantation for refractory Crohn's disease
- Seon Ho Bak, Hyun Ho Choi, Jinhee Lee, Mi Hee Kim, Youn Hee Lee, Jin Su Kim, Young-Seok Cho
- Intest Res 2017;15(2):244-248. Published online April 27, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.2.244
-
Abstract
PDFPubReaderePub
Approximately one-third of patients with Crohn's disease do not respond to conventional treatments, and some experience significant adverse effects, such as serious infections and lymphoma, and many patients require surgery due to complications. Increasing evidence suggests that specific changes in the composition of gut microbiota, termed as dysbiosis, are a common feature in patients with inflammatory bowel disease (IBD). Dysbiosis can lead to activation of the mucosal immune system, resulting in chronic inflammation and the development of mucosal lesions. Recently, fecal microbiota transplantation, aimed at modifying the composition of gut microbiota to overcome dysbiosis, has become a potential alternative therapeutic option for IBD. Herein, we present a patient with Crohn's colitis in whom biologic therapy failed previously, but clinical remission and endoscopic improvement was achieved after a single fecal microbiota transplantation infusion.
-
Citations
Citations to this article as recorded by- Epigenetics and the role of nutraceuticals in health and disease
Amr El-Sayed, Lotfi Aleya, Mohamed Kamel
Environmental Science and Pollution Research.2023; 30(11): 28480. CrossRef - Crohn’s disease: Etiology, pathogenesis and treatment strategies
Izel Aycan BASOGLU, Berna KARAKOYUN
Marmara Medical Journal.2023; 36(2): 249. CrossRef - Alteration of microbiota antibody‐mediated immune selection contributes to dysbiosis in inflammatory bowel diseases
Eva Michaud, Louis Waeckel, Rémi Gayet, Roman Goguyer‐Deschaumes, Blandine Chanut, Fabienne Jospin, Katell Bathany, Magali Monnoye, Coraline Genet, Amelie Prier, Caroline Tokarski, Philippe Gérard, Xavier Roblin, Nicolas Rochereau, Stéphane Paul
EMBO Molecular Medicine.2022;[Epub] CrossRef - Gut microbiota: A new target for T2DM prevention and treatment
Lulu Liu, Jiheng Zhang, Yi Cheng, Meng Zhu, Zhifeng Xiao, Guangcong Ruan, Yanling Wei
Frontiers in Endocrinology.2022;[Epub] CrossRef - Current Trends and Challenges of Fecal Microbiota Transplantation—An Easy Method That Works for All?
Cátia Almeida, Rita Oliveira, Pilar Baylina, Rúben Fernandes, Fábio G. Teixeira, Pedro Barata
Biomedicines.2022; 10(11): 2742. CrossRef - Bibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021
Fengwei Zhang, Peilin Yang, Yilin Chen, Ruirui Wang, Baocheng Liu, Jianying Wang, Min Yuan, Lei Zhang
Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef - Fecal microbiota transplantation for Crohn’s disease: a systematic review and meta-analysis
F. Cheng, Z. Huang, W. Wei, Z. Li
Techniques in Coloproctology.2021; 25(5): 495. CrossRef - Management of Clostridioides difficile infection in patients with inflammatory bowel disease
Sahil Khanna
Intestinal Research.2021; 19(3): 265. CrossRef - Microbiota and epigenetics: promising therapeutic approaches?
Amr El-Sayed, Lotfi Aleya, Mohamed Kamel
Environmental Science and Pollution Research.2021; 28(36): 49343. CrossRef - Improving the Gut Microbiota with Probiotics and Faecal Microbiota Transplantation
Yogita M. Patil, Rajashree B. Patwardhan, Pragati S. Abhyankar
Journal of Pure and Applied Microbiology.2021; 15(3): 1111. CrossRef - Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome
Yonghyun Lee, Nobuhiko Kamada, James J. Moon
Advanced Drug Delivery Reviews.2021; 179: 114021. CrossRef - Alteration of Gut Microbiota in Autism Spectrum Disorder: An Overview
Donghun Oh, Keun-Ah Cheon
Journal of the Korean Academy of Child and Adolescent Psychiatry.2020; 31(3): 131. CrossRef - Development of the Korean Form of the Premonitory Urge for Tics Scale: A Reliability and Validity Study
Mira Kim, Sang-Keun Chung, Jong-Chul Yang, Jong-Il Park, Seok Hyun Nam, Tae Won Park
Journal of the Korean Academy of Child and Adolescent Psychiatry.2020; 31(3): 146. CrossRef - Secondary causes of inflammatory bowel diseases
Yezaz A Ghouri, Veysel Tahan, Bo Shen
World Journal of Gastroenterology.2020; 26(28): 3998. CrossRef - Fecal microbiota transplantation in the treatment of Crohn disease
Miranda Collins, Morgan DeWitt
JAAPA.2020; 33(9): 34. CrossRef - Inflammatory Bowel Diseases: The Role of Gut Microbiota
Cristiana De Musis, Lucia Granata, Marcello Dallio, Agnese Miranda, Antonietta G. Gravina, Marco Romano
Current Pharmaceutical Design.2020; 26(25): 2951. CrossRef - The human-microbiome superorganism and its modulation to restore health
E. Salvucci
International Journal of Food Sciences and Nutrition.2019; 70(7): 781. CrossRef - The microbiome, cancer, and cancer therapy
Beth A. Helmink, M. A. Wadud Khan, Amanda Hermann, Vancheswaran Gopalakrishnan, Jennifer A. Wargo
Nature Medicine.2019; 25(3): 377. CrossRef - RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
Jung Hoon Song, You Sun Kim
Gut and Liver.2019; 13(1): 16. CrossRef - Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery
Michael Kriss, Keith Z Hazleton, Nichole M Nusbacher, Casey G Martin, Catherine A Lozupone
Current Opinion in Microbiology.2018; 44: 34. CrossRef - Microbiota transplantation: concept, methodology and strategy for its modernization
Faming Zhang, Bota Cui, Xingxiang He, Yuqiang Nie, Kaichun Wu, Daiming Fan
Protein & Cell.2018; 9(5): 462. CrossRef - The hygiene hypothesis at a glance: Early exposures, immune mechanism and novel therapies
Gabriel M. Alexandre-Silva, Pablo A. Brito-Souza, Ana C.S. Oliveira, Felipe A. Cerni, Umberto Zottich, Manuela B. Pucca
Acta Tropica.2018; 188: 16. CrossRef - The Safety of Fecal Microbiota Transplantation for Crohn’s Disease: Findings from A Long-Term Study
Honggang Wang, Bota Cui, Qianqian Li, Xiao Ding, Pan Li, Ting Zhang, Xiaozhong Yang, Guozhong Ji, Faming Zhang
Advances in Therapy.2018; 35(11): 1935. CrossRef - Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
Chang Soo Eun
Intestinal Research.2017; 15(2): 145. CrossRef - Diagnosis and treatment of Crohn's disease
Hyun-Soo Kim
Journal of the Korean Medical Association.2017; 60(6): 484. CrossRef
- Epigenetics and the role of nutraceuticals in health and disease
- 6,645 View
- 64 Download
- 24 Web of Science
- 25 Crossref
Original Article
- Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients
- Shinta Mizuno, Kosaku Nanki, Katsuyoshi Matsuoka, Keiichiro Saigusa, Keiko Ono, Mari Arai, Shinya Sugimoto, Hiroki Kiyohara, Moeko Nakashima, Kozue Takeshita, Makoto Naganuma, Wataru Suda, Masahira Hattori, Takanori Kanai
- Intest Res 2017;15(1):68-74. Published online January 31, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.1.68
-
Abstract
PDFSupplementary MaterialPubReaderePub
<b>Background/Aims</b><br/> Recent developments in analytical techniques including next-generation sequencing have clarified the correlation between intestinal microbiota and inflammatory bowel disease. Fecal microbiota transplantation (FMT) for patients with ulcerative colitis (UC) is proposed as a potential approach to resolving their dysbiosis; however, its safety and efficacy have not been confirmed. This single-arm, open-label, non-randomized study aimed to evaluate the safety and efficacy of FMT for Japanese patients with UC as the first registered clinical trial in Japan.
Methods We enrolled 10 patients with active UC despite medical therapy. The donors were the patients' relatives and were carefully screened for infectious diseases. Fecal material was administered via colonoscopy, and the primary endpoint was the presence or absence of serious adverse events related to FMT. The secondary endpoint was a change in partial Mayo score at 12 weeks post-FMT. Scores ≤2 were considered a clinical response. Fecal samples were collected to follow changes in gut microbiota, while extracted complementary DNA were analyzed by a next-generation sequencer. We obtained written informed consent from all patients and donors. This study was approved by our Institutional Review Board and is registered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN 000012814).
Results Five patients with moderate disease and five with severe disease were enrolled. No severe adverse effects were observed. One patient achieved clinical response; however, none of the patients' microbiota diversity recovered to the donor levels.
Conclusions The use of single FMT for UC was safe; however, we failed to show its clinical efficacy and potential to change the intestinal microbiota.
-
Citations
Citations to this article as recorded by- Single-Donor and Pooling Strategies for Fecal Microbiota Transfer Product Preparation in Ulcerative Colitis: A Systematic Review and Meta-analysis
Benoît Levast, Mathieu Fontaine, Stéphane Nancey, Pierre Dechelotte, Joël Doré, Philippe Lehert
Clinical and Translational Gastroenterology.2023; 14(5): e00568. CrossRef - Recipient-independent, high-accuracy FMT-response prediction and optimization in mice and humans
Oshrit Shtossel, Sondra Turjeman, Alona Riumin, Michael R. Goldberg, Arnon Elizur, Yarin Bekor, Hadar Mor, Omry Koren, Yoram Louzoun
Microbiome.2023;[Epub] CrossRef - Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial
Andreas Stallmach, Philip Grunert, Johannes Stallhofer, Bettina Löffler, Michael Baier, Jürgen Rödel, Michael Kiehntopf, Sophie Neugebauer, Dietmar H. Pieper, Howard Junca, Andrea Tannapfel, Ute Merkel, Ulrike Schumacher, Maria Breternitz-Gruhne, Tabitha
Trials.2022;[Epub] CrossRef - An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis
Taobi Huang, Jinlan Xu, Maoying Wang, Ke Pu, Longquan Li, Huiyun Zhang, Yuan Liang, Weiming Sun, Yuping Wang
Medicine.2022; 101(30): e29790. CrossRef - Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
Xiaochen Zhang, Dai Ishikawa, Toshifumi Ohkusa, Shinji Fukuda, Akihito Nagahara
Frontiers in Medicine.2022;[Epub] CrossRef - The Effects of Multi-Donor Fecal Microbiota Transplantation Capsules Combined with Thalidomide on Hormone-Dependent Ulcerative Colitis
Xiao-He Guo, Yan-Li Zhu, Lu Yang, Wen-Jing Li, Xue-Fang Du
Infection and Drug Resistance.2022; Volume 15: 7495. CrossRef - Fecal microbiota transplantation for ulcerative colitis
Katsuyoshi Matsuoka
Immunological Medicine.2021; 44(1): 30. CrossRef - Bacteriotherapy for inflammatory bowel disease
Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai
Inflammation and Regeneration.2021;[Epub] CrossRef - Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis
Valentin Mocanu, Sabitha Rajaruban, Jerry Dang, Janice Y. Kung, Edward C. Deehan, Karen L. Madsen
Journal of Clinical Medicine.2021; 10(5): 959. CrossRef - Current status, complications and prospects of fecal microbiota transplantation therapy
Ohara Tadashi
Archives of Pathology and Clinical Research.2021; 5(1): 004. CrossRef - Fecal Microbial Transplantation in Critically Ill Patients—Structured Review and Perspectives
Ivana Cibulková, Veronika Řehořová, Jan Hajer, František Duška
Biomolecules.2021; 11(10): 1459. CrossRef - Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation
Herbert L. DuPont, Zhi-Dong Jiang, Andrew W. DuPont, Netanya S. Utay
Digestive Diseases and Sciences.2020; 65(3): 741. CrossRef - Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
Journal of Digestive Diseases.2020; 21(3): 147. CrossRef - Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis
Luciane de Fátima Caldeira, Helena H. Borba, Fernanda S. Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo, Udai P. Singh
PLOS ONE.2020; 15(9): e0238910. CrossRef - Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy
Ajit Sood, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Dina Kao, David T Rubin, Charles N Bernstein
Crohn's & Colitis 360.2020;[Epub] CrossRef - Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta‐analysis
Hai Lan Zhao, Shu Zhen Chen, Hao Ming Xu, You Lian Zhou, Jie He, Hong Li Huang, Jing Xu, Yu Qiang Nie
Journal of Digestive Diseases.2020; 21(10): 534. CrossRef - Fecal Microbiota Transplantation in Intestinal Disorders: A Primer for Physicians
Ajit Sood, Vandana Midha, Harmeet Kaur, Arshdeep Singh
Journal of Gastrointestinal Infections.2020; 10(1): 16. CrossRef - Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of
steroid-dependent ulcerative colitis
Young-Seok Cho
Intestinal Research.2019; 17(1): 6. CrossRef - RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
Jung Hoon Song, You Sun Kim
Gut and Liver.2019; 13(1): 16. CrossRef - 1) Microbiota and Gastrointestinal Diseases
Takanori Kanai
Nihon Naika Gakkai Zasshi.2019; 108(3): 401. CrossRef - Fecal microbial transplantation
Sonia Bouri, Ailsa Hart
Current Opinion in Clinical Nutrition & Metabolic Care.2018; 21(5): 405. CrossRef - The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis
Yantian Cao, Bangjie Zhang, Yuanyuan Wu, Qingzhi Wang, Jie Wang, Fangfang Shen
Gastroenterology Research and Practice.2018; 2018: 1. CrossRef - Gut microbiota‐immune‐brain interactions in chemotherapy‐associated behavioral comorbidities
Kelley R. Jordan, Brett R. Loman, Michael T. Bailey, Leah M. Pyter
Cancer.2018; 124(20): 3990. CrossRef - Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
Current Infectious Disease Reports.2018;[Epub] CrossRef - Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
Chang Soo Eun
Intestinal Research.2017; 15(2): 145. CrossRef - Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome
Shinta Mizuno, Tatsuhiro Masaoka, Makoto Naganuma, Taishiro Kishimoto, Momoko Kitazawa, Shunya Kurokawa, Moeko Nakashima, Kozue Takeshita, Wataru Suda, Masaru Mimura, Masahira Hattori, Takanori Kanai
Digestion.2017; 96(1): 29. CrossRef - Intestinal immune response is regulated by gut microbe
Shun TANEMOTO, Tomohisa SUJINO, Takanori KANAI
Japanese Journal of Clinical Immunology.2017; 40(6): 408. CrossRef
- Single-Donor and Pooling Strategies for Fecal Microbiota Transfer Product Preparation in Ulcerative Colitis: A Systematic Review and Meta-analysis
- 8,187 View
- 98 Download
- 26 Web of Science
- 27 Crossref
Case Report
-
Refractory
Clostridium difficile Infection Cured With Fecal Microbiota Transplantation in Vancomycin-Resistant Enterococcus Colonized Patient - Mi-Ok Jang, Jun Hwan An, Sook-In Jung, Kyung-Hwa Park
- Intest Res 2015;13(1):80-84. Published online January 29, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.1.80
-
Abstract
PDFPubReader
The rates and severity of
Clostridium difficile infections, including pseudomembranous colitis, have increased markedly. However, there are few effective treatments for refractory or recurrentC. difficile infections and the outcomes are poor. Fecal microbiota transplantation is becoming increasingly accepted as an effective and safe intervention in patients with recurrent disease, likely due to the restoration of a disrupted microbiome. Cure rates of >90% are being consistently reported from multiple centers. We cured a case of severe refractoryC. difficile infection with fecal microbiota transplantation in a patient colonized by vancomycin-resistant enterococcus.-
Citations
Citations to this article as recorded by- The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases
Rohma Ghani, Benjamin H. Mullish, Lauren A. Roberts, Frances J. Davies, Julian R. Marchesi
Gut Microbes.2022;[Epub] CrossRef - Make It Less difficile: Understanding Genetic Evolution and Global Spread of Clostridioides difficile
Mariachiara Mengoli, Monica Barone, Marco Fabbrini, Federica D’Amico, Patrizia Brigidi, Silvia Turroni
Genes.2022; 13(12): 2200. CrossRef - Colonization Dynamics of Multidrug-Resistant Klebsiella pneumoniae Are Dictated by Microbiota-Cluster Group Behavior over Individual Antibiotic Susceptibility: A Metataxonomic Analysis
János Juhász, Balázs Ligeti, Márió Gajdács, Nóra Makra, Eszter Ostorházi, Ferenc Balázs Farkas, Balázs Stercz, Ákos Tóth, Judit Domokos, Sándor Pongor, Dóra Szabó
Antibiotics.2021; 10(3): 268. CrossRef - Successful use of early, repeat fecal microbiota transplantation for initial treatment of severe, refractory Clostridioides difficile colitis
Catherine M Cappetto
American Journal of Health-System Pharmacy.2021; 78(15): 1374. CrossRef - Fecal microbiota transplantation for antibiotic resistant bacteria decolonization
Sophie Amrane, Jean-Christophe Lagier
Human Microbiome Journal.2020; 16: 100071. CrossRef - Faecal microbiota transplantation for the decolonization of antibiotic-resistant bacteria in the gut: a systematic review and meta-analysis
V. Tavoukjian
Journal of Hospital Infection.2019; 102(2): 174. CrossRef - Fifty shades of graft: How to improve the efficacy of faecal microbiota transplantation for decolonization of antibiotic-resistant bacteria
Benjamin Davido, Rui Batista, Aurélien Dinh, Pierre de Truchis, E.M. Terveer, Bruce Roberts, Ed J. Kuijper, Silvia Caballero
International Journal of Antimicrobial Agents.2019; 53(5): 553. CrossRef - RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
Jung Hoon Song, You Sun Kim
Gut and Liver.2019; 13(1): 16. CrossRef - Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review
S. Saha, R. Tariq, P.K. Tosh, D.S. Pardi, S. Khanna
Clinical Microbiology and Infection.2019; 25(8): 958. CrossRef - Gut Microbiota Modulation for Multidrug-Resistant Organism Decolonization: Present and Future Perspectives
Livia Gargiullo, Federica Del Chierico, Patrizia D’Argenio, Lorenza Putignani
Frontiers in Microbiology.2019;[Epub] CrossRef - Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection
Young Kyung Yoon, Jin Woong Suh, Eun-Ji Kang, Jeong Yeon Kim
Annals of Medicine.2019; 51(7-8): 379. CrossRef - The Role of Fecal Microbiota Transplantation in Reducing Intestinal Colonization With Antibiotic-Resistant Organisms: The Current Landscape and Future Directions
Michael H Woodworth, Mary K Hayden, Vincent B Young, Jennie H Kwon
Open Forum Infectious Diseases.2019;[Epub] CrossRef - Design and application of oral colon administration system
Hao Cheng, Shiyu Huang, Gangliang Huang
Journal of Enzyme Inhibition and Medicinal Chemistry.2019; 34(1): 1590. CrossRef - The Intestinal Microbiota as a Reservoir and a Therapeutic Target to Fight Multi-Drug-Resistant Bacteria: A Narrative Review of the Literature
Andrea Aira, Csaba Fehér, Elisa Rubio, Alex Soriano
Infectious Diseases and Therapy.2019; 8(4): 469. CrossRef - Intestinal microbiota and antibiotic resistance: Perspectives and solutions
Climent Casals-Pascual, Andrea Vergara, Jordi Vila
Human Microbiome Journal.2018; 9: 11. CrossRef - The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms
Srinivasa Nithin Gopalsamy, Michael H. Woodworth, Tiffany Wang, Cynthia T. Carpentieri, Nirja Mehta, Rachel J. Friedman-Moraco, Aneesh K. Mehta, Christian P. Larsen, Colleen S. Kraft
The American Journal of the Medical Sciences.2018; 356(5): 433. CrossRef - Mechanisms of antimicrobial resistance among hospital-associated pathogens
Ayesha Khan, William R. Miller, Cesar A. Arias
Expert Review of Anti-infective Therapy.2018; 16(4): 269. CrossRef - The commensal microbiota exacerbate infectious colitis in stressor-exposed mice
Jeffrey D. Galley, Nicola M. Parry, Brian M.M. Ahmer, James G. Fox, Michael T. Bailey
Brain, Behavior, and Immunity.2017; 60: 44. CrossRef - Microbial approaches for targeting antibiotic‐resistant bacteria
Wing Fei Wong, Marina Santiago
Microbial Biotechnology.2017; 10(5): 1047. CrossRef - Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
Erik R. Dubberke, Kathleen M. Mullane, Dale N. Gerding, Christine H. Lee, Thomas J. Louie, Harriet Guthertz, Courtney Jones
Open Forum Infectious Diseases.2016;[Epub] CrossRef - Can Fecal Microbiota Transplantation (FMT) Eradicate Fecal Colonization With Vancomycin-Resistant Enterococci (VRE)?
Kyung Mok Sohn, Shinhye Cheon, Yeon-Sook Kim
Infection Control & Hospital Epidemiology.2016; 37(12): 1519. CrossRef - Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives
Hyun Ho Choi, Young-Seok Cho
Clinical Endoscopy.2016; 49(3): 257. CrossRef
- The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases
- 5,922 View
- 44 Download
- 24 Web of Science
- 22 Crossref
First
Prev
